No more Nordisk: Novo’s latest trim is in its name
When Mike Doustdar joined Novo Nordisk as CEO, he emphasised corporate evolution. Now, a year later, he has delivered a…
News
Pressure intensifies on Novartis as bolt-on deal strategy faces major test
Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval
HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir
Exegenesis Bio and Modalis sign research deal for Duchenne therapy
ABEC to expand global manufacturing network with new Wilson facility
Encoded secures $275m for Dravet syndrome gene therapy
Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion
